The two faces of serotonin in bone biology

Journal of Cell Biology

Volumn 191, Issue 1, 2010, Pages 7-13

  Ducy, Patricia ^a   Karsenty, Gerard ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NEUROTRANSMITTER; SEROTONIN; TRYPTOPHAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP5 PROTEIN, HUMAN; LRP5 PROTEIN, MOUSE; TPH1 PROTEIN, HUMAN; TRYPTOPHAN HYDROXYLASE; WNT PROTEIN;

BONE; BONE MASS; BONE REMODELING; BRAIN; HUMAN; INTESTINE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; BIOSYNTHESIS; BONE DEVELOPMENT; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE REMODELING; HUMANS; LDL-RECEPTOR RELATED PROTEINS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MICE; OSTEOGENESIS; SEROTONIN; SIGNAL TRANSDUCTION; TRYPTOPHAN HYDROXYLASE; WNT PROTEINS;

EID: 77957747818     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.201006123     Document Type: Review

References (68)

1. Ashcroft, G.W., T.B. Crawford, D. Eccleston, D.F. Sharman, E.J. MacDougall, J.B. Stanton, and J.K. Binns. 1966. 5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. Lancet. 2:1049-1052. doi:10.1016/S0140-6736(66)92028-9
2. Aston-Jones, G., H. Akaoka, P. Charléty, and G. Chouvet. 1991. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J. Neurosci. 11:760-769.
3. Balthasar, N., R. Coppari, J. McMinn, S.M. Liu, C.E. Lee, V. Tang, C.D. Kenny, R.A. McGovern, S.C. Chua Jr., J.K. Elmquist, and B.B. Lowell. 2004. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron. 42:983-991. doi:10.1016/j.neuron.2004.06.004
4. Berger, M., J.A. Gray, and B.L. Roth. 2009. The expanded biology of serotonin. Annu. Rev. Med. 60:355-366. doi:10.1146/annurev.med.60.042307.110802
5. Bhanot, P., M. Brink, C.H. Samos, J.C. Hsieh, Y. Wang, J.P. Macke, D. Andrew, J. Nathans, and R. Nusse. 1996. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 382:225-230. doi:10.1038/382225a0
6. Bilezikian, J.P. 2009. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am. J. Med. 122:S14-S21. doi:10.1016/j.amjmed.2008.12.003
7. Boyden, L.M., J. Mao, J. Belsky, L. Mitzner, A. Farhi, M.A. Mitnick, D. Wu, K. Insogna, and R.P. Lifton. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346:1513-1521. doi:10.1056/NEJMoa013444
8. Brunkow, M.E., J.C. Gardner, J. Van Ness, B.W. Paeper, B.R. Kovacevich, S. Proll, J.E. Skonier, L. Zhao, P.J. Sabo, Y. Fu, et al. 2001. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68:577-589. doi:10.1086/318811
9. Calapai, G., F. Corica, A. Corsonello, L. Sautebin, M. Di Rosa, G.M. Campo, M. Buemi, V.N. Mauro, and A.P. Caputi. 1999. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J. Clin. Invest. 104:975-982. doi:10.1172/JCI5867 (Pubitemid 29536347)
10. Charnay, Y., I. Cusin, P.G. Vallet, P. Muzzin, F. Rohner-Jeanrenaud, and C. Bouras. 2000. Intracerebroventricular infusion of leptin decreases serotonin transporter binding sites in the frontal cortex of the rat. Neurosci. Lett. 283:89-92. doi:10.1016/S0304-3940(00)00951-4 (Pubitemid 30156740)
11. Clevers, H. 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127:469-480. doi:10.1016/j.cell.2006.10.018
12. Collet, C., C. Schiltz, V. Geoffroy, L. Maroteaux, J.M. Launay, and M.C. de Vernejoul. 2008. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J. 22:418-427. doi:10.1096/fj.07-9209com (Pubitemid 351225578)
13. Coppen, A., D.M. Shaw, and J.P. Farrell. 1963. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet. 1:79-81. doi:10.1016/S0140-6736(63)91084-5
14. Coppen, A., P.C. Whybrow, R. Noguera, R. Maggs, and A.J. Prange Jr. 1972. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch. Gen. Psychiatry. 26:234-241.
15. Day, T.F., X. Guo, L. Garrett-Beal, and Y. Yang. 2005. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell. 8:739-750. doi:10.1016/j.devcel.2005.03.016
16. Dhillon, H., J.M. Zigman, C. Ye, C.E. Lee, R.A. McGovern, V. Tang, C.D. Kenny, L.M. Christiansen, R.D. White, E.A. Edelstein, et al. 2006. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron. 49:191-203. doi:10.1016/j.neuron. 2005.12.021
17. Ducy, P., M. Amling, S. Takeda, M. Priemel, A.F. Schilling, F.T. Beil, J. Shen, C. Vinson, J.M. Rueger, and G. Karsenty. 2000. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 100:197-207. doi:10.1016/S0092-8674(00)81558-5 (Pubitemid 30064908)
18. Ebeling, P.R., and R.G. Russell. 2003. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. Int. J. Clin. Pract. 57:710-718. (Pubitemid 37428209)
19. Fernández-Galaz, M.C., S. Diano, T.L. Horvath, and L.M. Garcia-Segura. 2002. Leptin uptake by serotonergic neurones of the dorsal raphe. J. Neuroendocrinol. 14:429-434. doi:10.1046/j.1365-2826.2002.00783.x
20. Freese, J.L., D. Pino, and S.J. Pleasure. 2010. Wnt signaling in development and disease. Neurobiol. Dis. 38:148-153. doi:10.1016/j.nbd.2009.09. 003
21. Friedman, J.M., and J.L. Halaas. 1998. Leptin and the regulation of body weight in mammals. Nature. 395:763-770. doi:10.1038/27376 (Pubitemid 28485436)
22. Frost, M., T.E. Andersen, V.K. Yadav, K. Brixen, G. Karsenty, and M. Kassem. 2010. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J. Bone Miner. Res. 25:673-675. doi:10.1002/jbmr.44
23. Gershon, M.D., and J. Tack. 2007. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 132:397-414. doi:10.1053/j.gastro.2006.11.002
24. Gingrich, J.A., and R. Hen. 2001. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl.). 155:1-10. doi:10.1007/s002130000573
25. Glass, D.A., II, P. Bialek, J.D. Ahn, M. Starbuck, M.S. Patel, H. Clevers, M.M. Taketo, F. Long, A.P. McMahon, R.A. Lang, and G. Karsenty. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell. 8:751-764. doi:10.1016/j.devcel.2005.02.017 (Pubitemid 40585297)
26. Gong, Y., R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. Cundy, F.H. Glorieux, D. Lev, et al. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 107:513-523. doi:10.1016/S0092-8674(01)00571-2
27. Grahame-Smith, D.G. 1964. Tryptophan hydroxylation in brain. Biochem. Biophys. Res. Commun. 16:586-592. doi:10.1016/0006-291X(64)90197-4
28. Hay-Schmidt, A., L. Helboe, and P.J. Larsen. 2001. Leptin receptor immunoreactivity is present in ascending serotonergic and catecholaminergic neurons of the rat. Neuroendocrinology. 73:215-226. doi:10.1159/000054638 (Pubitemid 32424515)
29. Heath, M.J., and R. Hen. 1995. Serotonin receptors. Genetic insights into serotonin function. Curr. Biol. 5:997-999. doi:10.1016/S0960-9822(95)00199-0
30. Hetherington, A.W. 1940. Hypothalamic lesions and adiposity in the rat. Anat. Rec. 78:149-172. doi:10.1002/ar.1090780203
31. Hill, T.P., D. Später, M.M. Taketo, W. Birchmeier, and C. Hartmann. 2005. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell. 8:727-738. doi:10.1016/j.devcel. 2005.02.013
32. Hodsman, A.B., D.C. Bauer, D.W. Dempster, L. Dian, D.A. Hanley, S.T. Harris, D.L. Kendler, M.R. McClung, P.D. Miller, W.P. Olszynski, et al. 2005. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26:688-703. doi:10.1210/er.2004-0006
33. Holland, J.M. 1976. Serotonin deficiency and prolonged bleeding in beige mice. Proc. Soc. Exp. Biol. Med. 151:32-39.
34. Karsenty, G. 2006. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4:341-348. doi:10.1016/j.cmet.2006. 10.008 (Pubitemid 44645074)
35. Karsenty, G., H.M. Kronenberg, and C. Settembre. 2009. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 25:629-648. doi:10.1146/annurev. cellbio.042308.113308
36. Kato, M., M.S. Patel, R. Levasseur, I. Lobov, B.H. Chang, D.A. Glass II, C. Hartmann, L. Li, T.H. Hwang, C.F. Brayton, et al. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157:303-314. doi:10.1083/jcb.200201089 (Pubitemid 34839826)
37. Kaumann, A.J., and F.O. Levy. 2006. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 111:674-706. doi:10.1016/j. pharmthera.2005.12.004 (Pubitemid 44118434)
38. Kramer, I., C. Halleux, H. Keller, M. Pegurri, J.H. Gooi, P.B. Weber, J.Q. Feng, L.F. Bonewald, and M. Kneissel. 2010. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 30:3071-3085. doi:10.1128/MCB.01428-09
39. Li, X., M.S. Ominsky, Q.T. Niu, N. Sun, B. Daugherty, D. D'Agostin, C. Kurahara, Y. Gao, J. Cao, J. Gong, et al. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23:860-869. doi:10.1359/jbmr.080216
40. Lobov, I.B., S. Rao, T.J. Carroll, J.E. Vallance, M. Ito, J.K. Ondr, S. Kurup, D.A. Glass, M.S. Patel, W. Shu, et al. 2005. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature. 437:417-421. doi:10.1038/nature03928
41. Lovenberg, W., E. Jequier, and A. Sjoerdsma. 1967. Tryptophan hydroxylation: measurement in pineal gland, brainstem, and carcinoid tumor. Science. 155:217-219. doi:10.1126/science.155.3759.217
42. Mann, J.J., P.A. McBride, R.P. Brown, M. Linnoila, A.C. Leon, M. DeMeo, T. Mieczkowski, J.E. Myers, and M. Stanley. 1992. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch. Gen. Psychiatry. 49:442-446.
43. Michelson, D., J.D. Amsterdam, F.M. Quitkin, F.W. Reimherr, J.F. Rosenbaum, J. Zajecka, K.L. Sundell, Y. Kim, and C.M. Beasley Jr. 1999. Changes in weight during a 1-year trial of fluoxetine. Am. J. Psychiatry. 156:1170-1176. (Pubitemid 29374875)
44. Moon, R.T., A.D. Kohn, G.V. De Ferrari, and A. Kaykas. 2004. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5:691-701. doi:10.1038/nrg1427
45. Parr, B.A., and A.P. McMahon. 1994. Wnt genes and vertebrate development. Curr. Opin. Genet. Dev. 4:523-528. doi:10.1016/0959-437X(94)90067-D
46. Rapport, M.M., A.A. Green, and I.H. Page. 1948a. Crystalline Serotonin. Science. 108:329-330. doi:10.1126/science.108.2804.329
47. Rapport, M.M., A.A. Green, and I.H. Page. 1948b. Serum vasoconstrictor, serotonin; isolation and characterization. J. Biol. Chem. 176:1243-1251.
48. Rodan, G.A., and T.J. Martin. 2000. Therapeutic approaches to bone diseases. Science. 289:1508-1514. doi:10.1126/science.289.5484.1508
49. Russell, R.G. 2007. Bisphosphonates: mode of action and pharmacology. Pediatrics. 119:S150-S162. doi:10.1542/peds.2006-2023H
50. Saarinen, A., T. Saukkonen, T. Kivelä, U. Lahtinen, C. Laine, M. Somer, S. Toiviainen-Salo, W.G. Cole, A.E. Lehesjoki, and O. Mäkitie. 2010. Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin. Endocrinol. (Oxf.). 72:481-488. doi:10.1111/j.1365-2265.2009.03680.x
51. Saudou, F., and R. Hen. 1994. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem. Int. 25:503-532. doi:10.1016/0197- 0186(94)90150-3
52. Scott, M.M., J.L. Lachey, S.M. Sternson, C.E. Lee, C.F. Elias, J.M. Friedman, and J.K. Elmquist. 2009. Leptin targets in the mouse brain. J. Comp. Neurol. 514:518-532. doi:10.1002/cne.22025
53. Sjoerdsma, A. 1959. Serotonin. N. Engl. J. Med. 261:181-188. doi:10.1056/NEJM195907232610406
54. Sjoerdsma, A., and M.G. Palfreyman. 1990. History of serotonin and serotinin disorders. Ann. N. Y. Acad. Sci. 600:1-7, discussion 7-8. doi:10.1111/j.1749-6632.1990.tb16869.x
55. Takeda, S., F. Elefteriou, R. Levasseur, X. Liu, L. Zhao, K.L. Parker, D. Armstrong, P. Ducy, and G. Karsenty. 2002. Leptin regulates bone formation via the sympathetic nervous system. Cell. 111:305-317. doi:10.1016/S0092-8674(02) 01049-8 (Pubitemid 35345151)
56. Tamai, K., M. Semenov, Y. Kato, R. Spokony, C. Liu, Y. Katsuyama, F. Hess, J.P. Saint-Jeannet, and X. He. 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature. 407:530-535. doi:10.1038/35035117
57. Teitelbaum, S.L., and F.P. Ross. 2003. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4:638-649. doi:10.1038/nrg1122 (Pubitemid 36917505)
58. van Bezooijen, R.L., P. ten Dijke, S.E. Papapoulos, and C.W. Löwik. 2005. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16:319-327. doi:10.1016/j.cytogfr.2005. 02.005
59. Vegni, F.E., C. Corradini, and G. Privitera. 2004. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N. Engl. J. Med. 350:189-192, author reply 189-192. doi:10.1056/NEJM200401083500219
60. Wagner, E.F., and G. Karsenty. 2001. Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11:527-532. doi:10.1016/S0959-437X(00) 00228-8
61. Walther, D.J., and M. Bader. 2003. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66:1673-1680. doi:10.1016/S0006- 2952(03)00556-2
62. Walther, D.J., J.U. Peter, S. Bashammakh, H. Hörtnagl, M. Voits, H. Fink, and M. Bader. 2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 299:76. doi:10.1126/science.1078197
63. Yadav, V.K., and P. Ducy. 2010. Lrp5 and bone formation : A serotonin-dependent pathway. Ann. N. Y. Acad. Sci. 1192:103-109. doi:10.1111/j.1749-6632.2009.05312.x
64. Yadav, V.K., J.H. Ryu, N. Suda, K.F. Tanaka, J.A. Gingrich, G. Schütz, F.H. Glorieux, C.Y. Chiang, J.D. Zajac, K.L. Insogna, et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 135:825-837. doi:10.1016/j.cell.2008.09.059
65. Yadav, V.K., F. Oury, N. Suda, Z.W. Liu, X.B. Gao, C. Confavreux, K.C. Klemenhagen, K.F. Tanaka, J.A. Gingrich, X.E. Guo, et al. 2009. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 138:976-989. doi:10.1016/j.cell.2009.06. 051
66. Yadav, V.K., H.P. Arantes, E.R. Barros, M. Lazaretti-Castro, and P. Ducy. 2010a. Genetic analysis of Lrp5 function in osteoblast progenitors. Calcif. Tissue Int. 86:382-388. doi:10.1007/s00223-010-9350-7
67. Yadav, V.K., S. Balaji, P.S. Suresh, X.S. Liu, X. Lu, Z. Li, X.E. Guo, J.J. Mann, A.K. Balapure, M.D. Gershon, et al. 2010b. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. 16:308-312. doi:10.1038/nm.2098
68. Zhang, Y., R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425-432. doi:10.1038/372425a0